Science1 publisher2 min readPublished
FDA's final rule swaps "animal studies" for "nonclinical studies" from next February
The FDA will accept methods other than animal testing for drug and biologic safety determinations when it judges them appropriate, and the agency decides for itself what appropriate means.
The Scientist · Science desk
What happened
- The FDA's final rule says that from next February, research methods other than animal testing can be used when "appropriate" to determine the safety of drugs and biologics.
- The rule works by substituting terms: "animal tests" and "animal studies" in the regulatory text become "nonclinical tests" and "nonclinical studies".
- NIH announced several initiatives the same day to encourage non-animal approaches, naming cell-based assays, organs-on-a-chip and computer models.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint A sponsor cannot design a validation package around the word "appropriate". Whether a chip assay substitutes for a rodent study stays a case-by-case review judgement.
- decision Programmes whose nonclinical packages close after February 2027 have to choose between funding animal and non-animal work in parallel or settling the question with the agency in advance.
- precedent With the regulation's vocabulary now species-neutral, FDA can widen or narrow acceptable methods through guidance without reopening the rule.
The change is in the vocabulary of the regulation. Where the text said "animal tests" and "animal studies", it now says "nonclinical tests" and "nonclinical studies" [3]. The requirement stays in place and the species drops out of it, so a cell-based assay or a computer model can satisfy it when the agency considers the method appropriate [1]. "Nonclinical" is the wider category and animal work still sits inside it, which means nothing here stops a sponsor from running the rat study [15].
"We are moving HHS toward a new era of biomedical research that puts human biology at the center of science," health secretary Robert F. Kennedy Jr. said in a statement [6]. It is the second set of strategies HHS has announced this year to speed a shift toward human-based research methods and reduce the use of animals in medical testing [5].
NIH's half of the announcement encourages cell-based assays, organs-on-a-chip and computer models [4]. STAT's accounts skip dollar figures and program mechanisms for those initiatives [14], and neither item says how the FDA will decide that a given method is appropriate for a given safety question [13].
The date is the part a preclinical planner can put in a budget. STAT's Morning Rounds newsletter, published September 23, said the final rule was issued the previous day [8], and the Pharmalot item reporting the rule ran on September 22 [9], so the rule dates from September 22, 2026 [10]. The next February after that is February 2027 [11]. Counting forward from September 22 to February 1 gives 132 days [12].
Whether a submission that puts liver-chip data where a rodent toxicology study used to sit will clear review is still an open question. The rule permits the method, and acceptance turns on the "appropriate" condition, written into the rule as a judgement [1]. STAT's Ed Silverman, who wrote the account of the new policies, spoke with advocates on both sides of the long-running debate [7].
What to watch
- FDA guidance that names an acceptable non-animal method for a specific safety endpoint. Guidance like that would turn permission into something a sponsor can validate against.
- Dollar figures and program structure for the NIH initiatives. STAT did not report either.
- The first publicly identified submission in which organ-chip or in-silico data stands in for an animal study and clears review.